Hair loss

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

Retrieved on: 
Monday, January 8, 2024
Scalp, BHT, Division, Transplant, FUE, Hair loss, Harbor–UCLA Medical Center, Surgeon, Skin, Eyebrow, Specialization, Eyelash, Patient, Wound healing, Cosmetics

LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss.

Key Points: 
  • LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss.
  • A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal titled ' Beard and Body Hair Transplantation by Follicular Unit Excision Using a Skin-Responsive Device .'
  • This publication introduces the revolutionary UGraft Zeus®, a novel skin-responsive device empowering doctors to seamlessly relocate beard and body hair to bald areas on the scalp through a procedure known as body hair transplantation (BHT).
  • Specialized transplants like eyebrows, beards, and eyelashes achieve more natural aesthetic results by utilizing matched body hair characteristics compared to thick but unmatched scalp hair.

Immusoft To Present on ISP-001 Clinical Trial at WORLDSymposium™ 2024 Conference

Retrieved on: 
Wednesday, January 3, 2024
Research, Genetics, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Immunosuppression, Lysosomal storage disease, Conference, Risk, Infection, Iduronidase, Bone marrow, Hair loss, Infertility, Disease, Enzyme replacement therapy, Nausea, MPS I, Immune system, Clinical trial, MPS, University, ERT, Corporation, IDUA, ISP, Cell, Patient, Cell biology, Genetic engineering, Vaccine

Immusoft Corporation , a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024.

Key Points: 
  • Immusoft Corporation , a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024.
  • Immusoft is developing a new modality of gene encoded medicine that holds the promise of being durable and redosable.
  • The Company’s lead investigational drug candidate ISP-001, is a first-in-class investigational treatment for mucopolysaccharidosis type I (MPS I), a rare lysosomal storage disease.
  • In this first-in-human clinical trial, the patient was dosed without the need for a preconditioning regimen (required for gene modified stem cells) or immunosuppression (required for most systemic virus-delivered gene therapy).

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Constipation, INN, Leukopenia, Woman, Carcinoma, Lung cancer, Fatigue, Nausea, DNA, Cancer, Neoplasm, Infection, SCLC, Mouth ulcer, Risk management, Anatomy, Paclitaxel, IIA, CHMP, Diarrhea, Fever, ATC, Capsule, European, Disease, Weakness, Mucositis, Anemia, Medical Subject Headings, Febrile neutropenia, European Commission, Cyclophosphamide, Vincristine, International, Neutropenia, Somatic symptom disorder, Aplastic anemia, Language, Cisplatin, Thrombocytopenia, Medication, Select, Patient, Medicine, Vomiting, Ovary, Survival, Ovarian cancer, Cervical cancer, Hair loss, Radiation, Doxorubicin, Committee, Medical device

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Stomach, Liver, Medical Subject Headings, Diarrhea, Marketing, Prostate cancer, Neck, Prednisolone, Stomatitis, Breast, INN, Cyclophosphamide, HER2, Breast cancer, ATC, Trastuzumab, Hair loss, International, Stomach cancer, Prednisone, Lung cancer, Weakness, Neutropenia, Nausea, Language, Mouth, Cisplatin, Cancer, Inflammation, Head, Testosterone, Neoplasm, Dexamethasone, Neutrophil, Blood, Non-small-cell lung cancer, Capecitabine, European Medicines Agency, Skeleton, Fluorouracil, Doxorubicin, Select, Cell, Patient, Anatomy, Medicine, Anemia, Vomiting, IIA, Prostate, Medical imaging

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

VATANMED Hair Transplantation Clinic Has Announced Its New Service Sapphire FUE

Retrieved on: 
Wednesday, December 6, 2023
Scalp, Trauma, Learning, Hair loss, Health, Knowledge, Patient, Follicular unit extraction, Dentistry

Istanbul, Turkey--(Newsfile Corp. - December 6, 2023) - VATANMED hair transplantation clinic, a renowned center for hair transplant and plastic surgery based in Istanbul, is proud to announce the introduction of its latest service - Sapphire FUE.

Key Points: 
  • Istanbul, Turkey--(Newsfile Corp. - December 6, 2023) - VATANMED hair transplantation clinic, a renowned center for hair transplant and plastic surgery based in Istanbul, is proud to announce the introduction of its latest service - Sapphire FUE.
  • This advanced technique represents a significant leap in hair restoration technology, offering a less invasive, more effective solution for hair loss.
  • Sapphire FUE, or Follicular Unit Extraction using sapphire blades, is a groundbreaking approach in hair transplant surgery.
  • With a presence in various continents, including Europe, America, and Africa, VATANMED has garnered a unique and diverse experience in the field of hair transplantation.

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Retrieved on: 
Tuesday, December 12, 2023
Liver, Atopic dermatitis, Eosinophilic bronchitis, Partnership, Dermatology, ASLN, Alopecia areata, Hair loss, Disease, MD, SAN, JAK, Beacon Grand Hotel, IGA, EASI, Institutional review board, TREK, DHODH, Patient, Safety, AA, Skin

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
  • “Throughout 2023, ASLAN made major progress on multiple fronts – advancing both of our lead programs, eblasakimab and farudodstat in Phase 2 testing, and establishing business development collaborations to further the development and utilization of eblasakimab,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.
  • ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
  • Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

Global Carboxy Therapy Market Analysis and Forecast to 2028, by Type, Application, End User and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 26, 2023
Health, Other Health, Skin, UNDP, Tabletop, Digital, CVI, Pain management, Midaeium, Aesthetics, Hair loss, Prevalence, Wound healing, Ageing, Hospital, Incidence, Region, Cellulite, DSM-IV codes, Social media, Growth, System, Safety, Calibration, Carboxytherapy, PAD, Pharmaceutical industry

The "Global Carboxy Therapy Market: Analysis and Trends by Type, Application, End User and Region and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Carboxy Therapy Market: Analysis and Trends by Type, Application, End User and Region and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global carboxy therapy market value in 2022 stood at US$95.64 million, and is likely to reach US$191.32 million by 2028.
  • Carboxytherapy is well-suited to address these issues, making it a desirable option for the aging demographic, leading to the growth of carboxy therapy market.
  • Global Carboxy therapy Market Dynamics:
    Growth Drivers: Versatile application has the potential to boost the growth of the carboxy therapy market.

THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR

Retrieved on: 
Wednesday, December 27, 2023
SOCS, Master of Science, Inflammation, Congress, Health, National Medical Association, MPH, Symposium, Travel, Howard University, Procter & Gamble, Collection, Resident, Marriott Marquis, Eli Lilly, MBA, Challenge, Health equity, Strata Skin Sciences, Avita Medical, Physician, DF, WCD, UCB, La Roche-Posay, DEI, Patient, Medicine, L'Oréal, FAAD, Hair loss, DRS, Patient safety, Education, International League, Google Health, Inclusion, Volunteering, Summit, Bristol Myers Squibb, AbbVie, Pharmaceutical industry

Several signature SOCS programs and newer initiatives that took place this year made uniquely important contributions to the field, as follows.

Key Points: 
  • Several signature SOCS programs and newer initiatives that took place this year made uniquely important contributions to the field, as follows.
  • Right" and much more, this enlightening collection addresses many issues of importance to patients of color and the physicians who care for them.
  • 8 Travel Grants to the SOCS Meeting the Challenge Summit awarded to Dermatology Residents, supported by Summit sponsorships.
  • 48 SOCS Mentor-Mentee pairings in the SOCS Mentorship program were facilitated, thanks to individual donations made to the SOCS Foundation.

Hairmax® Announces New Expansion into the European Union

Retrieved on: 
Monday, November 20, 2023
Beauty, Growth, Top Model, Hair loss, European, B2C, BOCA, Management

This strategic collaboration marks a significant leap towards delivering state-of-the-art hair growth solutions to a wide customer base in the European Union.

Key Points: 
  • This strategic collaboration marks a significant leap towards delivering state-of-the-art hair growth solutions to a wide customer base in the European Union.
  • John Beerens operates seamlessly in both B2B and B2C realms, standing out as the premier online beauty marketplace.
  • Renowned for its commitment to exclusivity and innovation, John Beerens provides top-notch advice and the most cutting-edge, reliable products to its diverse clientele.
  • We're eager to broaden our influence in the region by joining forces with John Beerens, a leading and innovative online beauty marketplace."

Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Retrieved on: 
Wednesday, November 15, 2023
SUN, Feedback, Safety, Deucravacitinib, JAK, HUB, Patient satisfaction, Dermatology, AA, Baricitinib, Patient, Alopecia areata, Element, FDA, Benchmarking, Lilly, Hair loss, Launch, Upadacitinib, Communication, Physician, Horizon, Education, Pharmaceutical industry, Marketing, Pfizer

Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.

Key Points: 
  • Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.
  • Prescribers of both brands express high and comparable satisfaction levels, far surpassing the satisfaction rates associated with non-advanced systemic treatment options.
  • Recent data from Spherix's published studies highlight minimal differentiation among prescribers regarding the two JAK inhibitors.
  • Furthermore, barriers preventing increased use of either JAK inhibitor remain closely contested, with safety concerns topping the list for each asset.